Quarterly report pursuant to Section 13 or 15(d)

Long-Term Debt and Other Financings - Novartis Note (Details)

v3.21.2
Long-Term Debt and Other Financings - Novartis Note (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended
Oct. 21, 2020
Jun. 30, 2021
May 31, 2005
Sep. 30, 2021
Sep. 30, 2020
Jun. 30, 2021
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2017
Dec. 31, 2015
Dec. 31, 2020
Sep. 30, 2015
Long-term debt                        
Revenue from contracts with customers       $ 550 $ 200   $ 1,094 $ 753        
Loss on extinguishment of debt             (300)          
Novartis Note [Member]                        
Long-term debt                        
Research and development expenses funded through loan facility, maximum (as a percent)     75.00%                  
Maximum borrowing capacity under loan agreement     $ 50,000                  
Amount by which note will be reduced upon achievement of specified milestones                       $ 7,300
Reduction in debt obligation $ 7,300 $ 9,100                    
Debt amount       0     0       $ 9,100  
Loss on extinguishment of debt           $ 0            
Novartis Note [Member] | Six-month LIBOR [Member]                        
Long-term debt                        
Basis spread on variable rate     2.00%                  
Novartis International [Member] | License Agreement [Member]                        
Long-term debt                        
Revenue from contracts with customers 25,000     $ 0 $ 0   $ 0 $ 0 $ 10,000 $ 37,000    
Cash payment received $ 17,700                 $ 37,000